Purpose: To evaluate the surgical results of pars plana vitrectomy with peeling of the inner limiting membrane (ILM) in a preliminary series of 28 eyes with macular epiretinal membrane (ERM). Methods: Pars plana vitrectomy with peeling of the ERM was performed on 28 eyes. All preretinal macular tissues were removed including the ILM after injection of indocyanine green (ICG) solution. Results: Postoperatively visual acuity improved within 3 months by at least 2 lines in 26 eyes. Neither the deterioration of the macula nor the recurrence of the ERM was observed during the entire period of review (6 months; range 4–8 months). Conclusions: Vitrectomy including ICG-assisted peeling of the ERM leads to an expedited resolution of the macular pucker and improvement of visual acuity, without subsequent formation of ERMs.

1.
McDonald HR, Aaberg TM: Idiopathic epiretinal membranes. Semin Ophthalmol 1986;1:189–195.
2.
Noble KG, Carr RE: Idiopathic preretinal gliosis. Ophthalmology 1982;89:521–523.
3.
McDonald HR, Verre WP, Aaberg TM: Surgical management of idiopathic epiretinal membranes. Ophthalmology 1986;93:978–983.
4.
Wise GN: Preretinal macular fibrosis: An analysis of 90 cases. Trans Ophthalmol Soc UK 1972;92:131–140.
5.
Burke JM, Sigos E, Cross HE: Cell proliferation in response to vitreous hemoglobin. Invest Ophthalmol Vis Sci 1981;20:575–581.
6.
Burke JM, Smith JM: Retinal proliferation in response to vitreous hemoglobin or iron. Invest Ophthalmol Vis Sci 1981;20:582–592.
7.
Gass JDM: Macular dysfunction caused by vitreous and vitreoretinal interface abnormalities: Vitreous traction maculopathies; in Gass JDM (ed): Stereoscopic Atlas of Macular Diseases, Diagnosis and Treatment, ed 3. St Louis, Mosby, 1987, pp 676–693.
8.
Morris R, Witherspoon CD, Kuhn F, Preister B: Internal limiting membrane (ILM) maculorhexis for traction maculopathy. Vitreoret Surg Technol 1997;8:1–4.
9.
De Bustros S, Thompson JT, Michels RG, et al: Vitrectomy for idiopathic epiretinal membranes causing macular pucker. Br J Ophthalmol 1988;72:692–695.
10.
Michels RG, Gilbert HD: Surgical management of macular pucker after retinal reattachment surgery. Am J Ophthalmol 1979;88:925–929.
11.
De Bustros S, Rice TA, Michels RG, et al: Vitrectomy for macular pucker: Use after treatment of retinal tears or retinal detachment. Arch Ophthalmol 1988;106:758–760.
12.
Robertson DM, Buettner H: Pigmented preretinal membranes. Am J Ophthalmol 1977;83:824–829.
13.
Michels RG: A clinical and histopathologic study of epiretinal membranes affecting the macula and removed by vitreous surgery. Trans Am Ophthalmol Soc 1982;80:580.
14.
Trese MT, Chandler DB, Machemer R: Macular pucker. I. Prognostic criteria. Graefes Arch Clin Exp Ophthalmol 1984;221:12.
15.
Smiddy WE, Meguire A, Grun WR, et al: Idiopathic epiretinal membranes: Ultrastructural characteristics and clinicopathologic correlation. Ophthalmology 1989;96:811.
16.
Vinores SA, Campochiaro PA, Conway BP: Ultrastructural and electron immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci 1990;31:14–28.
17.
Michels RG: Macular pucker; in Ryan SJ (ed): Retina. St Louis, Mosby, 1985, vol III, pp 419–430.
18.
Shea M: The surgical management of macular pucker in rhegmatogenous retinal detachment. Ophthalmology 1980;87:70–74.
19.
Sivalingam A, Eagle RC Jr, Duker JS, et al: Visual prognosis correlated with the presence of internal-limiting membrane in histopathologic specimens obtained from epiretinal membrane surgery. Ophthalmology 1990;97:1549–1552.
20.
Rice TA, De Bustros S, Michels RG, et al: Prognostic factor in vitrectomy for epiretinal membranes of the macula. Ophthalmology 1986;93:602–610.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.